Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome （PRIME Study）

NCT05914155 is registered in ClinicalTrials.gov with Shoichi Maruyama MD PhD as lead sponsor.

NCT NCT05914155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05914155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome （PRIME Study）
Lead sponsor
Shoichi Maruyama MD PhD
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 24, 2023
Completion date
June 30, 2028
Enrollment
88 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

glomerulonephritis, membranous, nephrotic syndrome，idiopathic